MX2016014701A - (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. - Google Patents

(r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.

Info

Publication number
MX2016014701A
MX2016014701A MX2016014701A MX2016014701A MX2016014701A MX 2016014701 A MX2016014701 A MX 2016014701A MX 2016014701 A MX2016014701 A MX 2016014701A MX 2016014701 A MX2016014701 A MX 2016014701A MX 2016014701 A MX2016014701 A MX 2016014701A
Authority
MX
Mexico
Prior art keywords
pirlindole
pharmaceutically acceptable
acceptable salts
medicine
well
Prior art date
Application number
MX2016014701A
Other languages
English (en)
Other versions
MX368735B (es
Inventor
Marques Almeida Pecorelli Susana
Alberto Eufrásico CASIMIRO CAIXADO Carlos
Filipe Eufrásio Pedroso Pedro
Sofia Da Conceição Lopes Ana
Carlos Ramos DAMIL João
Eusébio PARDAL FILIPE Augusto
Original Assignee
Tecnimede Soc Tecnico-Medicinal S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc Tecnico-Medicinal S A filed Critical Tecnimede Soc Tecnico-Medicinal S A
Publication of MX2016014701A publication Critical patent/MX2016014701A/es
Publication of MX368735B publication Critical patent/MX368735B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

(R)-pirlindol o sus sales farmacéuticamente aceptables, así como composiciones farmacéuticas que comprenden el mismo para su uso en el tratamiento terapéutico y la prevención del dolor.
MX2016014701A 2014-05-09 2014-05-09 (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. MX368735B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000028 WO2015171004A1 (en) 2014-05-09 2014-05-09 (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine

Publications (2)

Publication Number Publication Date
MX2016014701A true MX2016014701A (es) 2017-05-23
MX368735B MX368735B (es) 2019-10-14

Family

ID=50819930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014701A MX368735B (es) 2014-05-09 2014-05-09 (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.

Country Status (29)

Country Link
US (2) US20170145015A1 (es)
EP (1) EP3054950B1 (es)
JP (1) JP2017514884A (es)
KR (1) KR102232198B1 (es)
CN (1) CN106413714A (es)
AU (1) AU2014393489B2 (es)
CA (1) CA2948596C (es)
CY (1) CY1119522T1 (es)
DK (1) DK3054950T3 (es)
EC (1) ECSP16086232A (es)
ES (1) ES2649491T3 (es)
HR (1) HRP20171650T1 (es)
HU (1) HUE035030T2 (es)
IL (1) IL248854B (es)
LT (1) LT3054950T (es)
MA (1) MA39448B1 (es)
MX (1) MX368735B (es)
NO (1) NO3054950T3 (es)
NZ (1) NZ726131A (es)
PH (1) PH12016502236A1 (es)
PL (1) PL3054950T3 (es)
PT (1) PT3054950T (es)
RS (1) RS56590B1 (es)
RU (1) RU2695607C2 (es)
SI (1) SI3054950T1 (es)
SM (1) SMT201700520T1 (es)
TN (1) TN2016000497A1 (es)
UA (1) UA116499C2 (es)
WO (1) WO2015171004A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA118587C2 (uk) * 2014-05-09 2019-02-11 Текнімеді Сос'Єдаді Текніку-Медісінал С.А. Фармацевтично прийнятні солі енантіомерів пірліндолу для застосування в медицині
UA116499C2 (uk) 2014-05-09 2018-03-26 Текнімеді Сос'Єдаді Текніку-Медісінал С.А. (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
KR102421013B1 (ko) 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
WO2019241564A1 (en) * 2018-06-13 2019-12-19 Children's Medical Center Corporation Biomarkers of neuropathic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
NZ541282A (en) * 2002-12-24 2009-02-28 Bellus Health International Ltd Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070043030A1 (en) * 2003-09-15 2007-02-22 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
TN2016000498A1 (en) * 2014-05-09 2018-04-04 Tecnimede Sociedade Tecnico Medicinal S (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine.
UA118587C2 (uk) * 2014-05-09 2019-02-11 Текнімеді Сос'Єдаді Текніку-Медісінал С.А. Фармацевтично прийнятні солі енантіомерів пірліндолу для застосування в медицині
UA116499C2 (uk) 2014-05-09 2018-03-26 Текнімеді Сос'Єдаді Текніку-Медісінал С.А. (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині

Also Published As

Publication number Publication date
ES2649491T3 (es) 2018-01-12
NO3054950T3 (es) 2017-12-30
KR102232198B1 (ko) 2021-03-26
US20170145015A1 (en) 2017-05-25
JP2017514884A (ja) 2017-06-08
US10533012B2 (en) 2020-01-14
HUE035030T2 (en) 2018-05-02
RU2016148182A3 (es) 2018-06-13
MX368735B (es) 2019-10-14
SI3054950T1 (sl) 2017-12-29
UA116499C2 (uk) 2018-03-26
RU2016148182A (ru) 2018-06-13
RS56590B1 (sr) 2018-02-28
KR20170003567A (ko) 2017-01-09
EP3054950B1 (en) 2017-08-02
HRP20171650T1 (hr) 2017-12-15
AU2014393489A1 (en) 2016-11-24
MA39448A1 (fr) 2018-08-31
MA39448B1 (fr) 2019-12-31
US20180111944A1 (en) 2018-04-26
CA2948596C (en) 2021-06-08
CA2948596A1 (en) 2015-11-12
IL248854A0 (en) 2017-01-31
PH12016502236A1 (en) 2017-02-06
PT3054950T (pt) 2017-11-29
RU2695607C2 (ru) 2019-07-24
NZ726131A (en) 2018-12-21
CY1119522T1 (el) 2018-03-07
WO2015171004A1 (en) 2015-11-12
TN2016000497A1 (en) 2018-04-04
IL248854B (en) 2020-05-31
CN106413714A (zh) 2017-02-15
LT3054950T (lt) 2017-11-27
EP3054950A1 (en) 2016-08-17
SMT201700520T1 (it) 2018-01-11
ECSP16086232A (es) 2017-02-24
AU2014393489B2 (en) 2020-01-02
DK3054950T3 (en) 2017-11-06
PL3054950T3 (pl) 2018-02-28

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX378273B (es) Compuestos activos hacia bromodominios.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
ES3057783T3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
CL2016003260A1 (es) Profármacos de gemcitabina
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
MX2016007410A (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
MX384447B (es) Composiciones farmacéuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.

Legal Events

Date Code Title Description
FG Grant or registration